Article
A prospective cluster trial to increase antibiotic prescription quality in seven non-ICU wards
Optimierung der Antibiotikaverschreibungsgüte auf sieben Normalstationen: eine prospektive Clusterstudie
Search Medline for
Authors
Published: | June 5, 2023 |
---|
Outline
Abstract
Aim: To evaluate general shortcomings and faculty-specific pitfalls as well as to improve antibiotic prescription quality (ABQ) in non-ICU wards, we performed a prospective cluster trial.
Methods: An infectious-disease (ID) consulting service performed a prospective investigation consisting of three 12-week phases with point prevalence evaluation conducted once per week (=36 evaluations in total) at seven non-ICU wards, followed by assessment of sustainability (weeks 37–48). Baseline evaluation (phase 1) defined multifaceted interventions by identifying the main shortcomings. Then, to distinguish intervention from time effects, the interventions were performed in four wards, and the 3 remaining wards served as controls; after assessing effects (phase 2), the same interventions were performed in the remaining wards to test the generalizability of the interventions (phase 3). The prolonged responses after all interventions were then analyzed in phase 4. ABQ was evaluated by at least two ID specialists who assessed the indication for therapy, the adherence to the hospital guidelines for empirical therapy, and the overall antibiotic prescription quality.
Results: In phase 1, 406 of 659 (62%) patients cases were adequately treated with antibiotics; the main reason for inappropriate prescription was the lack of an indication (107/253; 42%). The antibiotic prescription quality (ABQ) significantly increased, reaching 86% in all wards after the focused interventions (502/584; nDf=3, ddf=1,697, F=6.9, p=0.0001). In phase 2 the effect was only seen in wards that already participated in interventions (248/347; 71%). No improvement was seen in wards that received interventions only after phase 2 (189/295; 64%). A given indication significantly increased from about 80% to more than 90% (p<.0001). No carryover effects were observed.
Discussion: ABQ can be improved significantly by intervention bundles with apparent sustainable effects.
Zusammenfassung
Zielsetzung: Um häufige Fehler in der Antibiotikaverschreibung auf Normalstationen zu charakterisieren und die Verschreibungsgüte zu verbessern führten wir eine prospective Clusterstudie mit Intervention durch.
Methoden: Eine Punktprävalenzanalyse (1x/Woche) zur Antibiotikaverschreibungsgüte auf sieben Normalstationen einer Universitätsklinik wurde über 48 Monate (verteilt auf vier Phasen) durch ein Infektiologieteam durchgeführt. In Phase 1 wurden die häufigen Fehler charakterisiert. Um die Interventionseffekte von Zeit- oder unspezifischen Effekten zu unterscheiden, erhielten nach Phase 1 vier Stationen die auf Ihre Hauptfehler fokussierte Intervention. Die drei verbleibenden Stationen dienten als Kontrolle und erhielten die Intervention nach Phase 2. Der Interventionseffekt wurde während Phase 2 und 3 gemessen, die Frage des Anhaltens dieses Effekts ohne Intervention in Phase 4. Die Antibiotikaverschreibungsgüte wurde durch mindestens zwei Infektiologen unter Berücksichtigung lokaler Leitlinien durchgeführt.
Ergebnisse: In Phase 1 wurden 406/659 (62%) Patienten adäquat antibiotisch behandelt. Hauptursache für einen Fehler war das Fehlen einer Indikation (107/659, 16%; 107/253; 42%). Die Testgüte stieg signifikant auf allen Stationen unmittelbar nach erfolgter Intervention an auf 86% (502/584; nDf=3, ddf=1697, F=6.9, p=0.0001). In Phase 2 wurde dieser Effekt nur auf den “Interventionsstationen” beobachtet (248/347; 71%), auf den drei “Kontrollstationen” wurde kein Effekt gemessen (189/295; 64%). Das Vorliegen einer Indikation zur Antibiotikagabe stieg signifikant um ca. 80% an auf >90% (p<0.0001). Carryover Effekte wurden nicht gesehen.
Diskussion: Die Antibiotikaverschreibungsgüte kann signifikant durch fokussierte Interventionen zumindest mittelfristig gesteigert werden.
Introduction
It is generally accepted that multidrug resistant bacteria (MRB) and the infections they cause represent an increasing and worrisome healthcare issue. Moreover, the collateral damage of the “Janus-faced” antibiotics, e.g., Clostridiodis difficile infections, is a major concern [1], [2], [3]. There are virtually no completely new antibiotics in the current pharmaceutical pipeline [4]. Finally, this increase in infections not only lowers life quality of patients, but also leads to increased costs. This is because infections caused by MRB do not replace infections by less resistant microorganisms, but appear additionally [5]. As a consequence, this negatively impacts the already limited medical resources that many of us currently face. On top of the issues mentioned above, data published by the Cochrane Collaboration have highlighted the disturbing fact that around 50% of prescribed antibiotics are inappropriate [2]. Thus, there is clearly an urgent need to obtain more fundamental insights into how to improve antibiotic prescription quality.
One measure has been the introduction of antibiotic stewardship programs, which in some areas have been taken into law [6], [7], [8]. Over the last few years, the body of knowledge on antibiotic prescription quality and reasons for inappropriateness has dramatically increased [2], [6], [9], [10]. However, although many studies aiming at improving antibiotic prescription quality have been performed, not all succeeded in doing so [11]. Importantly, virtually all of these studies were performed in intensive care units (ICUs). Since 50–85% of in-house antibiotics are prescribed to patients in non-ICU wards, additional insights into antibiotic prescription quality for this relevant patient population are urgently required [12], [13], [14]. Moreover, interventions aiming at improving antibiotic prescription quality may have to consider different issues in these wards as well as individual faculty needs. Thus, intervention approaches should be tailored to the specific ward’s and faculty’s needs to produce appropriate antibiotic stewardship programs.
To this end, we conducted a prospective cluster trial using a protocol with three periods in seven non-ICU wards at a university hospital in Germany. This study aimed to [1] evaluate the main shortcomings and pitfalls in current antibiotic therapy, [2] perform interventions targeted at these critical points, and [3] define the impact of these interventions at increasing ABQ.
Methods
Setting
Since data on antibiotic usage from non-ICU wards are scarce, the present study included seven non-ICU wards, defining the clusters in the statistical analysis. The wards belonged to the following faculties: gastroenterology, nephrology/immunology, visceral/transplant surgery, orthopedics, cardiology/pneumology, traumatology, and cardiothoracic surgery.
Inclusion/exclusion criteria
Patients were included if they were present on that ward on the day of collection and were receiving antibiotics assumed to be for therapy of infectious diseases. Patients were excluded if they were not receiving antibiotic therapy on the day of enrollment or were receiving antibiotics for non-infectious reasons (e.g., rifampicin for liver protection, erythromycin for gastrointestinal motility).
Study design
Three 12-week phases during which point prevalence evaluation were conducted once per week and were interrupted by three 6- to 10-week phases, which were occasionally used for interventions. These interventions were performed directly after baseline observation in four wards: cardiology/pneumology, nephrology/immunology, visceral/transplant surgery, and orthopedics. The remaining three wards served as controls to distinguish true intervention effects from time trends and the Hawthorne effect during phase 2. To prove the universality of the approach, the same interventions were performed on these three wards (gastroenterology, traumatology, cardiothoracic surgery) after phase 2. Thus, the efficacy of the interventions and the prolonged effect of the interventions were assessed during phase 3. For a detailed timeline, see Figure 1 [Fig. 1].
All patients in any of the wards receiving antibiotics were enrolled on a weekly level, and antibiotic prescription practice was evaluated by a board of three infectious disease (ID) specialists. As before the study, the ID consultant service could be requested on demand for ID rounds and/or single ID case visits throughout the trial as necessary.
Endpoints
The purpose of this prospective cluster trial was to improve antibiotic prescription quality. To this end, we addressed two key questions:
- 1.
- How often is the antibiotic therapy appropriate and what are the main shortcomings and faculty-specific pitfalls at baseline?
- 2.
- What is the influence of the interventions on the rate of appropriateness? Thus, the endpoint was to assess whether the antibiotic therapy administered was appropriate or not depending on general and ward-specific interventions.
Since appropriateness quality is hard to define and because it considers many aspects and issues of antibiotic therapy [15], all of these have to be fulfilled for treatment to ultimately be regarded as appropriate. These aspects and issues are:
- adherence to the hospital guidelines in the empirical setting the pathogen-directed situation
- adequate dosing including adaptation given organ insufficiencies and allergies
- using the appropriate application form (sequential therapy)
- streamlining the therapeutic approach in accordance with the microbiological results
It should be mentioned that at the University Hospital Aachen, local guidelines for the empirical antibiotic therapy of the main infectious disease entities were already issued several years ago.
Interventions
The intervention strategies were communicated to all staff members and are based on the results obtained during the baseline phases and their interpretation. All interventions were targeted at the identified shortcomings and faculty-specific pitfalls.
On the individual ward, strategies were developed in interdisciplinary teams consisting of members of the ID consultant service and faculty/ward-specific physicians. The interventions comprised:
- teaching the principles of adequate antibiotic prescription
- distribution of already existing pocket cards explaining the empiric antibiotic therapy regimen based on local resistance patterns
- compilation and distribution of pocket cards for the best pathogen-oriented therapy regimen
- flow charts to facilitate better diagnoses (and thus improved prescription of an appropriate antibiotic regimen) for urinary tract infections
All wards received one instruction session in which all the results were presented along with interpretation of the same, aiming at improving antibiotic prescription quality. The other intervention tools were included upon the decision of ward- and faculty-specific physicians. One topic of special interest which represents a major issue antibiotic prescription quality is the indication for therapy in general. Thus, we also specifically analyzed this endpoint. The indication for therapy in general means that a given indication for antibiotic prescription was based on a highly suspected infection according to national and international criteria for diagnosing pneumonia, sepsis, urinary tract infections, bone and joint infections, endocarditis, surgical site infections, etc.
After all interventions were performed, a 4th phase was conducted according to the same rules as described for phases 1, 2 and 3, in order to define the sustainability of the achieved improvements.
The study was approved by the local ethics committee (head: Prof. Schmalzing; EK187/11).
Statistics
For data handling, a data management file using the Access program (Microsoft Office) was compiled and used.
We fitted generalized mixed-effects random-intercept models with logit links to the data of the response rates for “Indication for AB”; “Appropriate AB”; “Appropriate AB empirical setting”; “Appropriate AB pathogen-oriented setting”, taking into account the fixed effects intervention, in addition to phase as well as first and second order carryover effects. We assumed unstructed covariance within the clusters. Random intercept was applied to account for ward heterogeneity. PROC GLIMMIX (SAS® version 9.4 [TS1M1] under Windows X64 7 Pro was used for computations. Effects were considered significant at p<0.05. We described our results as odds ratios (OR) with corresponding 95% confidence intervals.
Results
The study started in November 2011 and ended in August 2013. A total of about 9,000 patient cases were enrolled during all four phases. During baseline observation, a total of 2,980 patient cases were enrolled, of which 659 (31%) were receiving antibiotics (Figure 2 [Fig. 2]).
During the first 12 weeks (baseline evaluation), 406/659 (62%) patient cases received appropriate antibiotic therapy. The appropriateness quality did not depend on the hospital setting in which antibiotics were used, i.e., the empirical setting versus pathogen-oriented setting (see Figure 2 [Fig. 2]). Using ward-specific analysis, the appropriateness ranged widely, from 47% to 81%. The intervention and control wards did not differ with regard to the number of patients treated with antibiotics and the rate of appropriateness at baseline. Despite a broad range of the appropriateness rate, the major shortcomings and pitfalls were the same on the individual wards. The main reason for inappropriateness was the lack of an indication (107/253; 42%). Prolonged antibiotic prophylaxis represented the main pitfall (57%) within this issue. The distribution of the other most common reasons for inappropriateness is illustrated in Table 1 [Tab. 1].
We observed infection rates of 359/476 (75%) in phase 1; 328/457 (72%) in phase 2, and 354/416 (85%) in phase 3. Compared to the primary endpoints in the 4th phase, a significant increase was observed with phase 1 (OR=0.33 95% CI, 0.18–0.63), phase 2 (OR=0.28 95% CI, 0.18–0.44) and phase 3 (OR=0.64 95% CI, 0.41–0.98). No significant carryover effects were observed (nDf=1, ddf=1,716, F=0.07, p=0.7880; nDf=1, ddf=1,716, F=0.55, p=0.4587) meaning that the treatment difference was not affected by the phases.
After the first intervention had taken place on the four intervention wards, the rate of appropriateness increased on each of these wards. In contrast, no changes were observed on any of the control wards (see Figure 3 [Fig. 3]). Compared to the last phase, the lack of appropriate antibiotic therapy showed a significant OR for phase 1 (OR=0.41; 95% CI, 0.20–0.83) and phase 2 (OR=0.37; 95% CI, 0.21–0.64). A sustained effect was also seen comparing phases 3 and 4, with a further improvement by trend (OR=0.80; 95% CI, 0.49–1.32). No significant carryover effects were observed (nDf=1, ddf=1,696, F=0.80, p =0.372; nDf=1, ddf=1,697, F=0.55, p=0.0697).
These significant improvements were documented for the empirical treatment setting (nDf=3, ddf=1,241, F=5.17, p=0.0015) as well as for the pathogen-oriented therapies (nDf=3, ddf=581, F=2.72, p=0.0435) (see Figure 2 [Fig. 2]). No significant carryover effects were observed for either setting (nDf=1, ddf=1,239, F=0.46, p=0.4993), (nDf=1, ddf=1,239, F=2.44, p=0.1185); (nDf=1, ddf=253.5, F=0.20, p=0.6586), (nDf=1, ddf=427.4, F=0.24, p=0.6219).
For ward-specific final results, see Figure 3 [Fig. 3]. The improvements seem to depend on the rate of adequate antibiotic therapy at baseline. The lower the rate at baseline, the greater the improvement.
The number of cases of Clostridiodis difficile infections was not affected; they occurred in 9, 20, 32, and 21 patients during phases 1–4, respectively.
Discussion
In summary, the key results of the four phases of this prospective cluster trial aimed at improving antibiotic prescription quality were as follows:
- 1.
- the number of patients receiving antibiotics was stable throughout the study;
- 2.
- all endpoints of interest improved;
- 3.
- the presence of an indication for the need to treat with antibiotics significantly increased from about 80% to more than 90%;
- 4.
- the main endpoint representing the rate of appropriate antibiotic therapy significantly increased from about 60% to more than 80%;
- 5.
- this finding was also true for empiric as well as pathogen-oriented therapies; and finally,
- 6.
- no carryover effects were observed.
Antibiotic misuse is common even in the field of professional medicine [2]. Reasons for overprescribing antibiotics must be defined to compile the best-fitting intervention strategies to sustainably overcome the problem. At non-ICU wards, however, neither the main general shortcomings nor the faculty-specific pitfalls that prevent better antibiotic prescription quality are still not fully known. A survey among US physicians revealed an approximately 90% agreement in antibiotic overuse in general. However, 20% of responders felt that they were using antibiotics optimally. Importantly, 90% of responders wanted more education and around 65% requested feedback on antibiotic treatment choices [16]. Similarly, a survey of medical students in Europe reported that about 74% of responders asked for more education about antibiotic treatment choices [17]. Taken together, these studies strongly emphasize the need for additional information and increased knowledge on how to improve antibiotic prescription quality.
It is noteworthy that, as we observed during our own interventions, the problems were not sophisticated, but instead were rather basic. For example, already existing pocket cards had to be distributed again, and the physicians asked for the most appropriate therapy on the pathogen level. In other words, with convenient tools and straight-forward strategies, a great improvement in antibiotic prescription quality could be achieved in our study.
In-house antibiotic standards have previously been documented to increase antibiotic prescription quality [18], [19]. Pathogen-oriented standards introduced during our interventions seemed to be even more important, since up to 60% of the antibiotics could be streamlined according to microbiological results [20], [21], [22], [23]. As our study demonstrated, the rate of improvement was higher when the baseline ABQ was lower. Further, our improvement rate at the least reached the approximately 10% improvement rates reported in the literature [24], [25], [26], [27], [28], [29].
Beyond these easily implementable tools and strategies, one stands out that is not easy to document and is related to a professional-ethics issue on antibiotic prescription. During instruction and ward rounds, many physicians argued that they were afraid to make a medical mistake when treating a patient without antibiotics. This issue was directly addressed during both the ID consultant services and ward rounds. In other studies, this tool was described as useful when aiming to improve antibiotic prescription quality [30], [31], [32]. During our study, we received varying requests from the different non-ICU wards. First, the major requests arose during phases 2 and 3, and second, only the orthopedics, traumatology, and cardiothoracic surgery wards requested ID visits on a weekly level. Our study showed that outcome did not depend solely on this issue.
Limitations
One limitation is the lack of randomization. This could result in selection bias. Another limitation is that no formal sample size calculation was made, which might result in an underpowered study.
Because the study was planned as observational, and randomization was difficult to organize for practical reasons (addressability and transferability to daily routine) we conducted the trials in a nonrandomized manner. Further, we were more interested on description of the effects and intended to provide some planning suggestions for a cluster-randomized trial.
Conclusions
At baseline, about 40% of antibiotic therapies were inappropriate. The major reasons for this were lack of indication, the therapy regimen lasting too long or being too broad, as well as an empirically false regimen on organisms that were not susceptible in vitro. After the interventions, these general shortcomings significantly decreased to less than 10% patients taking antibiotics without a true indication, and more than 85% patients were receiving an appropriate antibiotic regimen. Importantly, due to the design of this cluster trial, it seems that there will be positive lasting effects in terms of improved antibiotic prescription quality. For example, without any new intervention, the ABQ was observed to steadily increase. Even more importantly, only three wards asked for ID visits in phase four, indicating that a behavioral change had taken place and that physicians felt more competent when prescribing an appropriate antibiotic regime. For example, two of the surgery wards began analyzing all microbiological results on a daily basis. Note that at the start of the trial, microbiological results were only analyzed on a daily basis for patients who did not show adequate signs of recovery. Such an analysis is a basic requirement for the adaptation of antibiotic therapy in general and for streamlining in particular.
Finally, we attempted to correlate the improvements in overall antibiotic prescription quality with factors of collateral damage caused by the antibiotic administered. However, in contrast to other studies, we found no correlation between the rate of nosocomial Clostridium difficile infections and antibiotic prescription quality [2, 3]. This can be explained by the steady antibiotic usage rate per patient during the study. Antibiotic resistance, particularly in gram-negative rods, is rapidly increasing. Unfortunately, only a few new antibiotics are expected to be developed in the near future. Therefore, medical interventions aiming at improving appropriate antibiotic prescription practices are urgently needed. Using a portfolio of only a few basic tools and strategies, we succeeded not only in significantly increasing antibiotic prescription quality for more than two years, but also found indications that our trial will have long-lasting positive effects on antibiotic therapy.
Notes
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
Ralf-Dieter Hilgers appreciates the discussions about statistical analysis of the presented data with PD. Dr. Nicole Heussen and Prof. Dr. Maria Kateri, who were funded by the DAAD for the project “Poisson Response Models: Bayesian Analysis and Model Selection”.
Funding source
This study was partly funded by the EU Aspire Award 2013 given to Simone Scheithauer (a 47,500,– € grant) by Pfizer.
Ethical Statement
The study was approved by the local ethics committee (head: Prof. Schmalzing; EK187/11).
Transparency declaration
Nothing to declare.
References
- 1.
- Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014 Mar;370(13):1198-208. DOI: 10.1056/NEJMoa1306801
- 2.
- Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2005;4:CD003543. DOI: 10.1002/14651858.CD003543.pub2
- 3.
- Valiquette L, Cossette B, Garant MP, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007 Sep;45 Suppl 2:S112-21. DOI: 10.1086/519258
- 4.
- Spellberg B. The antibiotic crisis: can we reverse 65 years of failed stewardship? Arch Intern Med. 2011 Jun;171(12):1080-1. DOI: 10.1001/archinternmed.2011.26
- 5.
- Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, Herwaldt LA, van Keulen PH, Kluytmans JA, Kola A, Kuchenbecker RS, Lingaas E, Meessen N, Morris-Downes MM, Pottinger JM, Rohner P, dos Santos RP, Seifert H, Wisplinghoff H, Ziesing S, Walker AS, Bonten MJ. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis. 2013 Mar;56(6):798-805. DOI: 10.1093/cid/cis1006
- 6.
- Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsay CR, Wiffen PJ, Wilcox M. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003543. DOI: 10.1002/14651858.CD003543.pub3
- 7.
- Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012 Apr;33(4):338-45. DOI: 10.1086/664909
- 8.
- Goldman MP, Nair R. Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics? Cleve Clin J Med. 2007 Aug;74 Suppl 4:S38-47. DOI: 10.3949/ccjm.74.suppl_4.s38
- 9.
- Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007 Jan;44(2):159-77. DOI: 10.1086/510393
- 10.
- Davey P, Brown E, Fenelon L, Finch R, Gould I, Holmes A, Ramsay C, Taylor E, Wiffen P, Wilcox M. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis. 2006 Feb;12(2):211-6. DOI: 10.3201/eid1202.050145
- 11.
- Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011 Jun;66(6):1223-30. DOI: 10.1093/jac/dkr137
- 12.
- Zarb P, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. Drugs. 2011 Apr;71(6):745-55. DOI: 10.2165/11591180-000000000-00000
- 13.
- Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H; ESAC-3 Hospital Care Subproject Group. Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009. J Antimicrob Chemother. 2011 Feb;66(2):443-9. DOI: 10.1093/jac/dkq430
- 14.
- Ansari F, Erntell M, Goossens H, Davey P. The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. Clin Infect Dis. 2009 Nov;49(10):1496-504. DOI: 10.1086/644617
- 15.
- Bodí M, Ardanuy C, Olona M, Castander D, Diaz E, Rello J; Department of Critical Care, Hospital Univeristari Joan XXIII, Tarragona, Spain. Therapy of ventilator-associated pneumonia: the Tarragona strategy. Clin Microbiol Infect. 2001 Jan;7(1):32-3. DOI: 10.1046/j.1469-0691.2001.00187.x
- 16.
- Srinivasan A, Song X, Richards A, Sinkowitz-Cochran R, Cardo D, Rand C. A survey of knowledge, attitudes, and beliefs of house staff physicians from various specialties concerning antimicrobial use and resistance. Arch Intern Med. 2004 Jul;164(13):1451-6. DOI: 10.1001/archinte.164.13.1451
- 17.
- Dyar OJ, Pulcini C, Howard P, Nathwani D; ESGAP (ESCMID Study Group for Antibiotic Policies). European medical students: a first multicentre study of knowledge, attitudes and perceptions of antibiotic prescribing and antibiotic resistance. J Antimicrob Chemother. 2014 Mar;69(3):842-6. DOI: 10.1093/jac/dkt440
- 18.
- Martínez R, Reyes S, Lorenzo MJ, Menéndez R. Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med. 2009 Apr;30(2):172-8. DOI: 10.1055/s-0029-1202936
- 19.
- Bassi GL, Ferrer M, Saucedo LM, Torres A. Do guidelines change outcomes in ventilator-associated pneumonia? Curr Opin Infect Dis. 2010 Apr;23(2):171-7. DOI: 10.1097/QCO.0b013e328337241a
- 20.
- Huttner B, Jones M, Rubin MA, Madaras-Kelly K, Nielson C, Goetz MB, Neuhauser MM, Samore MH. Double trouble: how big a problem is redundant anaerobic antibiotic coverage in Veterans Affairs medical centres? J Antimicrob Chemother. 2012 Jun;67(6):1537-9. DOI: 10.1093/jac/dks074
- 21.
- Alvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan JM, Quintana E, Sanz-Rodriguez C; ADANN Study Group. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care. 2006;10(3):R78. DOI: 10.1186/cc4919
- 22.
- Mettler J, Simcock M, Sendi P, Widmer AF, Bingisser R, Battegay M, Fluckiger U, Bassetti S. Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. BMC Infect Dis. 2007 Mar;7:21. DOI: 10.1186/1471-2334-7-21
- 23.
- Montravers P, Dupont H, Gauzit R, Veber B, Bedos JP, Lepape A; Club d'Infectiologie en Anesthésie-Réanimation Study Group. Strategies of initiation and streamlining of antibiotic therapy in 41 French intensive care units. Crit Care. 2011;15(1):R17. DOI: 10.1186/cc9961
- 24.
- Schouten JA, Hulscher ME, Trap-Liefers J, Akkermans RP, Kullberg BJ, Grol RP, van der Meer JW. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis. 2007 Apr;44(7):931-41. DOI: 10.1086/512193
- 25.
- Jenkins TC, Knepper BC, Sabel AL, Sarcone EE, Long JA, Haukoos JS, Morgan SJ, Biffl WL, Steele AW, Price CS, Mehler PS, Burman WJ. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011 Jun;171(12):1072-9. DOI: 10.1001/archinternmed.2011.29
- 26.
- Grenier C, Pépin J, Nault V, Howson J, Fournier X, Poirier MS, Cabana J, Craig C, Beaudoin M, Valiquette L. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother. 2011 Jul;66(7):1617-24. DOI: 10.1093/jac/dkr176
- 27.
- Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, Lockhart PB. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011 May;342:d2392. DOI: 10.1136/bmj.d2392
- 28.
- Westphal JF, Jehl F, Javelot H, Nonnenmacher C. Enhanced physician adherence to antibiotic use guidelines through increased availability of guidelines at the time of drug ordering in hospital setting. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):162-8. DOI: 10.1002/pds.2078
- 29.
- Schnoor M, Meyer T, Suttorp N, Raspe H, Welte T, Schäfer T; CAPNETZ Study Group. Development and evaluation of an implementation strategy for the German guideline on community-acquired pneumonia. Qual Saf Health Care. 2010 Dec;19(6):498-502. DOI: 10.1136/qshc.2008.029629
- 30.
- Cosgrove SE, Patel A, Song X, Miller RE, Speck K, Banowetz A, Hadler R, Sinkowitz-Cochran RL, Cardo DM, Srinivasan A. Impact of different methods of feedback to clinicians after postprescription antimicrobial review based on the Centers For Disease Control and Prevention's 12 Steps to Prevent Antimicrobial Resistance Among Hospitalized Adults. Infect Control Hosp Epidemiol. 2007 Jun;28(6):641-6. DOI: 10.1086/518345
- 31.
- Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, O'Brien MA, Johansen M, Grimshaw J, Oxman AD. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012 Jun;(6):CD000259. DOI: 10.1002/14651858.CD000259.pub3
- 32.
- LaRocco A Jr. Concurrent antibiotic review programs – a role for infectious diseases specialists at small community hospitals. Clin Infect Dis. 2003 Sep;37(5):742-3. DOI: 10.1086/377286